These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23197369)

  • 21. [Economic evaluation of pharmacotherapies for smoking cessation].
    Antoñanzas F; Portillo F
    Gac Sanit; 2003; 17(5):393-403. PubMed ID: 14599422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost and effectiveness of the nationwide government-supported Smoking Cessation Clinics in the Republic of Korea.
    Oh JK; Lim MK; Yun EH; Shin SH; Park EY; Park EC
    Tob Control; 2013 May; 22(e1):e73-7. PubMed ID: 22752272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy and cost-effectiveness of smoking cessation courses in the statutory health insurance: a review].
    Rasch A; Greiner W
    Gesundheitswesen; 2009 Nov; 71(11):732-8. PubMed ID: 19492280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.
    Higashi H; Barendregt JJ
    Addiction; 2012 Mar; 107(3):658-70. PubMed ID: 21883602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The SmokingPaST Framework: illustrating the impact of quit attempts, quit methods, and new smokers on smoking prevalence, years of life saved, medical costs saved, programming costs, cost effectiveness, and return on investment.
    O'Donnell MP; Roizen MF
    Am J Health Promot; 2011; 26(1):e11-23. PubMed ID: 21879928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow.
    Boyd KA; Briggs AH
    Addiction; 2009 Feb; 104(2):317-25. PubMed ID: 19149829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right?
    Menzin J; Lines LM; Marton J
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):257-64. PubMed ID: 19527098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the cost-effectiveness of a high- and a low-intensity smoking cessation intervention in Sweden: a randomized trial.
    Nohlert E; Helgason AR; Tillgren P; Tegelberg A; Johansson P
    Nicotine Tob Res; 2013 Sep; 15(9):1519-27. PubMed ID: 23404735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy.
    Wilson K; Hettle R; Marbaix S; Diaz Cerezo S; Ines M; Santoni L; Annemans L; Prignot J; Lopez de Sa E
    Eur J Prev Cardiol; 2012 Oct; 19(5):1173-83. PubMed ID: 21840967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modelling a budgetary impact analysis for funding drug-based smoking cessation therapies for patients with major depressive disorder in Spain.
    Rejas-Gutiérrez J; Bruguera E; Cedillo S
    Eur Psychiatry; 2017 Sep; 45():41-49. PubMed ID: 28728094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
    Lock K; Wilson K; Murphy D; Riesco JA
    Expert Opin Pharmacother; 2011 Dec; 12(17):2613-26. PubMed ID: 22017336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.
    Bolin K; Mörk AC; Willers S; Lindgren B
    Respir Med; 2008 May; 102(5):699-710. PubMed ID: 18289839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The demand for health insurance coverage for tobacco dependence treatments: support for a benefit mandate and willingness to pay.
    Halpin HA; McMenamin SB; Shade SB
    Nicotine Tob Res; 2007 Dec; 9(12):1269-76. PubMed ID: 18058345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Smoking cessation in a blue-collar population: results from an evidence-based pilot program.
    Ringen K; Anderson N; McAfee T; Zbikowski SM; Fales D
    Am J Ind Med; 2002 Nov; 42(5):367-77. PubMed ID: 12382249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
    Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
    Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of internet and telephone treatment for smoking cessation: an economic evaluation of The iQUITT Study.
    Graham AL; Chang Y; Fang Y; Cobb NK; Tinkelman DS; Niaura RS; Abrams DB; Mandelblatt JS
    Tob Control; 2013 Nov; 22(6):e11. PubMed ID: 23010696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determining the cost-effectiveness of a computer-based smoking cessation intervention in primary care.
    Smith MY; Cromwell J; DePue J; Spring B; Redd W; Unrod M
    Manag Care; 2007 Jul; 16(7):48-55. PubMed ID: 17907712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective.
    Cedillo S; Sicras-Mainar A; Jiménez-Ruiz CA; Fernández de Bobadilla J; Rejas-Gutiérrez J
    Eur Addict Res; 2017; 23(1):7-18. PubMed ID: 27794567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of cardiovascular prevention programs in Spain.
    Plans-Rubió P
    Int J Technol Assess Health Care; 1998; 14(2):320-30. PubMed ID: 9611906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness of Integrating Tobacco Cessation Into Post-Traumatic Stress Disorder Treatment.
    Barnett PG; Jeffers A; Smith MW; Chow BK; McFall M; Saxon AJ
    Nicotine Tob Res; 2016 Mar; 18(3):267-74. PubMed ID: 25943761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.